Cingulate Inc. Announces Closing of Initial Public Offering
10 déc. 2021 11h00 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™...
Cingulate Inc. Announces Pricing of $25.0 Million Initial Public Offering
07 déc. 2021 21h05 HE
|
Cingulate Therapeutics LLC
KANSAS CITY, Kan., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™...